

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

1-35 (cancelled)

36. (Previously presented) A medicinal aerosol formulation, which consists essentially of:

- (a) a therapeutically effective amount of a particulate medicament;
- (b) a propellant; and
- (c) a suspension-enhancing material selected from an amino acid, an amino acid derivative, or a mixture of the foregoing,

whereby said medicament and said suspension-enhancing material are different.

37. (Previously presented) The formulation as defined in claim 36 wherein the medicament is selected from the group consisting of albuterol, atropine, beclomethasone dipropionate, budesonide, cromolyn, epinephrine, ephedrine, fentanyl, flunisolide, formoterol, ipratropium bromide, isoproterenol, pirbuterol, salmeterol, amiloride, (-)-4-amino-3,5-dichloro- α -[[[6(2-pyridinyl)ethoxy]hexyl]amino]methyl]benzene-methanol, and pharmaceutically acceptable salts, esters, hydrates, and solvates of the foregoing.

38. (Previously presented) The formulation as defined in claim 36, wherein said propellant is selected from the group consisting of 1,1,1,2-tetrafluoroethane, 1,1,1,2,3,3,3-heptafluoropropane or a mixture thereof.

39. (Previously presented) The formulation as defined in claim 36 wherein said suspension-enhancing material is present in an amount effective to prevent settling, creaming,

or flocculation of the formulation for a time sufficient to allow reproducible dosing of the drug after agitation of the formula.

40. (Previously presented) The formulation as defined in claim 39 wherein said suspension-enhancing material is present in an amount ranging from about 0.0001% by weight to about 20% by weight based on the weight of the formulation.

41. (Previously presented) A method of preparing a medicinal aerosol formulation according to claim 36, which comprises:

- (a) combining
 - (i) said medicament in an amount sufficient to provide a plurality of therapeutically effective doses;
 - (ii) said propellant in an amount sufficient to propel a plurality of said therapeutically effective doses from an aerosol canister; and
 - (iii) said suspension-enhancing material in an amount effective to enhance the suspension quality of the formulation; and
- (b) dispersing components (i), (ii), and (iii).

42. (Previously presented) A method of treating in an animal a condition capable of treatment by oral or nasal inhalation, which comprises, administering a formulation according to claim 36 to said animal by oral or nasal inhalation.

43. (Previously presented) A method of treating in an animal a condition capable of treatment by oral inhalation, which comprises, administering a formulation according to claim 36 to said animal by oral inhalation.
44. (Previously presented) A formulation according to claim 36 in an aerosol canister equipped with a metered dose valve.
45. (Previously presented) A method comprising incorporating into a formulation that includes a propellant and a particulate drug a suspension-enhancing material selected from the group consisting of a suitable amino acid, an amino acid derivative, or any mixture of the foregoing, in an amount which is effective to prevent settling, creaming, or flocculation of the formulation for a time sufficient to allow reproducible dosing of the drug after agitation of the formulation, whereby said drug and said amino acid, amino acid derivative, or mixture are different.
46. (Previously presented) A metered dose inhaler containing a medicinal aerosol formulation, the formulation consisting essentially of:
- (a) a drug in particulate form in a therapeutically effective amount;
 - (b) a propellant; and
 - (c) a suitable suspension-enhancing material selected from an amino acid, an amino acid derivative, or a mixture of the foregoing, present in an amount sufficient to prevent settling, creaming, or flocculation of the

formulation for a time sufficient to allow reproducible dosing of the drug after agitation of the formulation,
whereby said medicament and said suspension-enhancing material are different.

47. (Previously presented) The metered dose inhaler as defined in claim 46 wherein said suspension-enhancing material is present in an amount ranging from about 0.0001% by weight to about 20% by weight based on the weight of the medicinal aerosol formulation.

48. (Previously presented) The metered dose inhaler as defined in claim 46 wherein the medicament is selected from the group consisting of albuterol, atropine, beclomethasone dipropionate, budesonide, cromolyn, epinephrine, ephedrine, fentanyl, flunisolide, formoterol, ipratropium bromide, isoproterenol, pirbuterol, salmeterol, amiloride, (-)-4-amino-3,5-dichloro- α -[[[6(2-pyridinyl)ethoxy]hexyl]amino]methyl]benzene-methanol, and pharmaceutically acceptable salts, esters, hydrates, and solvates of the foregoing.

49. (Previously presented) The metered dose inhaler as defined in claim 46, wherein the propellant is selected from the group consisting of 1,1,1,2-tetrafluoroethane, 1,1,1,2,3,3,3-heptafluoropropane or a mixture thereof.

50. (Previously amended) A medicinal aerosol formulation which consists essentially of
(a) a therapeutically effective amount of a particulate medicament;
(b) a propellant; and

- (c) a suspension-enhancing material, in addition to the medicament,
selected from an amino acid, an amino acid derivative, or a mixture of the foregoing.

51. (Previously presented) A medicinal aerosol formulation, which consists essentially of:

- (a) a therapeutically effective amount of a particulate medicament;
- (b) a propellant; and
- (c) an amino acid, amino acid derivative, or a mixture of the
foregoing;

whereby said medicament of (a) and said amino acid, amino acid derivative, or mixture of (c) are different.

52. (Previously presented) The formulation as defined in claim 51 wherein the medicament is selected from the group consisting of albuterol, atropine, beclomethasone dipropionate, budesonide, cromolyn, epinephrine, ephedrine, fentanyl, flunisolide, formoterol, ipratropium bromide, isoproterenol, pirbuterol, salmeterol, amiloride, (-)-4-amino-3,5-dichloro- α -[[[6(2-pyridinyl)ethoxy]hexyl]amino]methyl]benzene-methanol, and pharmaceutically acceptable salts, esters, hydrates, and solvates of the foregoing.

53. (Previously presented) The formulation as defined in claim 51, wherein said propellant is selected from the group consisting of 1,1,1,2-tetrafluoroethane, 1,1,1,2,3,3,3-heptafluoropropane or a mixture thereof.

54. (Previously presented) The formulation as defined in claim 51 wherein said amino acid, amino acid derivative, or mixture is present in an amount effective to prevent settling, creaming, or flocculation of the formulation for a time sufficient to allow reproducible dosing of the drug after agitation of the formula.

55. (Previously presented) The formulation as defined in claim 54 wherein said amino acid, amino acid derivative, or mixture is present in an amount ranging from about 0.0001% by weight to about 20% by weight based on the weight of the formulation.

56. (Previously presented) A method of preparing a medicinal aerosol formulation according to claim 51, which comprises:

- (a) combining
 - (i) said medicament in an amount sufficient to provide a plurality of therapeutically effective doses;
 - (ii) said propellant in an amount sufficient to propel a plurality of said therapeutically effective doses from an aerosol canister; and
 - (iii) said amino acid, amino acid derivative, or mixture in an amount effective to enhance the stability of the formulation; and
- (b) dispersing components (i), (ii), and (iii).

57. (Previously presented) A method of treating in an animal a condition capable of treatment by oral or nasal inhalation, which comprises, administering a formulation according to claim 51 to said animal by oral or nasal inhalation.

58. (Previously presented) A method of treating in an animal a condition capable of treatment by oral inhalation, which comprises, administering a formulation according to claim 51 to said animal by oral inhalation.

59. (Previously presented) A formulation according to claim 51 in an aerosol canister equipped with a metered dose valve.

60. (Previously presented) A method comprising incorporating into a formulation that includes a propellant and a particulate drug a suitable amino acid, amino acid derivative, or any mixture of the foregoing, in an amount which is effective to prevent settling, creaming, or flocculation of the formulation for a time sufficient to allow reproducible dosing of the drug after agitation of the formulation, whereby said drug and said amino acid, amino acid derivative, or mixture are different.

61. (Previously presented) A metered dose inhaler containing a medicinal aerosol formulation, the formulation consisting essentially of:

- (a) a drug in particulate form in a therapeutically effective amount;
- (b) a propellant; and
- (c) an amino-acid, an amino acid derivative, or a mixture of the foregoing, present in an amount sufficient to prevent settling, creaming, or flocculation of the formulation for a time sufficient to allow reproducible dosing of the drug after agitation of the formulation

whereby said medicament of (a) and said amino acid, amino acid derivative, or mixture of (c) are different.

62. (Previously presented) The metered dose inhaler as defined in claim 61 wherein said amino acid, amino acid derivative, or mixture is present in an amount ranging from about 0.0001% by weight to about 20% by weight based on the weight of the medicinal aerosol formulation.

63. (Previously presented) The metered dose inhaler as defined in claim 61 wherein the medicament is selected from the group consisting of albuterol, atropine, beclomethasone dipropionate, budesonide, cromolyn, epinephrine, ephedrine, fentanyl, flunisolide, formoterol, ipratropium bromide, isoproterenol, pirbuterol, salmeterol, amiloride, (-)-4-amino-3,5-dichloro- α -[[[6(2-pyridinyl)ethoxy]hexyl]amino]methyl]benzene-methanol, and pharmaceutically acceptable salts, esters, hydrates, and solvates of the foregoing.

64. (Previously presented) The metered dose inhaler as defined in claim 61, wherein the propellant is selected from the group consisting of 1,1,1,2-tetrafluoroethane, 1,1,1,2,3,3,3-heptafluoropropane or a mixture thereof.

65. (Previously presented) A medicinal aerosol formulation which consists essentially of

- (a) a therapeutically effective amount of a particulate medicament;
- (b) a propellant; and

DOCKET NO.: CARP-0108
Application No.: 10/668,840
Office Action Dated: January 12, 2006

PATENT
REPLY FILED UNDER EXPEDITED
PROCEDURE PURSUANT TO
37 CFR § 1.116

(c) an amino acid, amino acid derivative, or a mixture of the foregoing, in addition to the medicament.